MedPath

Fexofenadine

Generic Name
Fexofenadine
Brand Names
Allegra, Allegra-D, Mucinex Non-drowsy Allergy, Wal-fex, Telfast
Drug Type
Small Molecule
Chemical Formula
C32H39NO4
CAS Number
83799-24-0
Unique Ingredient Identifier
E6582LOH6V
Background

Fexofenadine is an over-the-counter second-generation antihistamine used in the treatment of various allergic symptoms. It is selective for the H receptor, carries little-to-no activity at off-targets, and does not cross the blood-brain barrier - this is in contrast to previous first-generation antihistamines, such as diphenhydramine, which readily bind to off-targets that contribute to side effects such as sedation. Fexofenadine is the major active metabolite of terfenadine and is administered as a racemic mixture in which both enantiomers display approximately equivalent antihistamine activity.

Indication

In the United States, fexofenadine is indicated for the symptomatic treatment of allergic rhinitis in patients ≥2 years old and chronic idiopathic urticaria in patients ≥6 months old. In Canada, fexofenadine carries the same indications but is approved only for patients ≥12 years old. Fexofenadine is also available in combination with pseudoephedrine for the symptomatic treatment of season allergic rhinitis in patients ≥12 years old.

Associated Conditions
Allergic Rhinitis (AR), Chronic Idiopathic Urticaria, Seasonal Allergic Rhinitis
Associated Therapies
Antihistamine

Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma

Phase 3
Completed
Conditions
Asthma
First Posted Date
2002-09-17
Last Posted Date
2008-08-21
Lead Sponsor
Sanofi
Target Recruit Count
1000
Registration Number
NCT00044824
Locations
🇲🇽

Sanofi-Aventis Administrative Office, Mexico, Mexico

🇨🇷

Sanofi-Aventis Admnistrative Office, Costa Rica, Costa Rica

🇭🇺

sanofi-aventis Hungaria, Budapest, Hungary

and more 3 locations

Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma

Phase 3
Completed
Conditions
Asthma
First Posted Date
2002-09-17
Last Posted Date
2008-08-21
Lead Sponsor
Sanofi
Target Recruit Count
1000
Registration Number
NCT00044811
Locations
🇺🇸

Aventis Pharmaceuticals Inc., Bridgewater, New Jersey, United States

🇨🇷

Sanofi-Aventis Admnistrative Office, Costa Rica, Costa Rica

🇷🇺

Sanofi-Aventis Administrative Office, Moscow, Russian Federation

© Copyright 2025. All Rights Reserved by MedPath